EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Radioligand therapy in sympathetic-adrenal-medullary axis tumors: state of art and perspectives

Ilham Badrane, Luca Urso, Alfredo Campennì iD, Corrado Cittanti, Maria Luisa De Rimini, Mirco Bartolomei

Endocrine · 2024

DOI: 10.1007/s12020-024-04062-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine, 2024. Verfasst von Ilham Badrane und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Ferrara, Ferrara, Italy. Hauptthemen laut MEDLINE: Adrenal Gland Neoplasms, Pheochromocytoma, Radiopharmaceuticals, Neuroendocrine Tumors. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The approval in 2017 by the European Medicines Agency (EMA) and in 2018 by the US Food and Drug Administration (FDA) of radioligand therapy (RLT) led to its wide application in therapeutic management of neuroendocrine neoplasms (NENs). However, the indications are currently limited to certain specific histotypes belonging to the broader NEN's family, mainly advanced well-differentiated gastro-entero-pancreatic NENs. As a consequence, several other tumors of the NEN spectrum that can potentially benefit, due to their biological characteristics, from RLT are still ineligible and can be considered "RLT-orphans". Among those, the subgroup of NENs originating from the sympathetic-adrenal-medullary (SAM) axis can be listed. This paper discusses the state of art and perspectives of the theragnostic applications in pheochromocytomas and paragangliomas, considering both the traditional theragnostic model - with radiolabelled metaiodobenzylguanidine (MIBG) - and the innovative one with radiolabeled somatostatin analogs (SSAs), that will hopefully become available for these patients in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Gland NeoplasmsPheochromocytomaRadiopharmaceuticalsNeuroendocrine TumorsParaganglioma3-IodobenzylguanidineHumans

Stichwörter der Autor:innen

MIBGNENParagangliomaPheochromocytomaRLTTheranostics

Substanzen

Radiopharmaceuticals3-Iodobenzylguanidine

Autor:innen und Institutionen

  • Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
  • Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferarra, Italy.
  • Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy. acampenni@unime.it.
  • Unit of Nuclear Medicine, Department of Health Service, AO Colli Hospitals, Naples, Italy.

ORCID-Profile: Alfredo Campennì

Zitieren

APA

Badrane, I., Urso, L., Campennì, A., Cittanti, C., De Rimini, M. L., & Bartolomei, M. (2024). Radioligand therapy in sympathetic-adrenal-medullary axis tumors: state of art and perspectives. Endocrine. https://doi.org/10.1007/s12020-024-04062-1

Vancouver

Badrane I, Urso L, Campennì A, Cittanti C, De Rimini ML, Bartolomei M. Radioligand therapy in sympathetic-adrenal-medullary axis tumors: state of art and perspectives. Endocrine. 2024. doi:10.1007/s12020-024-04062-1

BibTeX
@article{Badrane2024,
  author = {Badrane, Ilham and Urso, Luca and Campennì, Alfredo and Cittanti, Corrado and De Rimini, Maria Luisa and Bartolomei, Mirco},
  title = {Radioligand therapy in sympathetic-adrenal-medullary axis tumors: state of art and perspectives},
  journal = {Endocrine},
  year = {2024},
  doi = {10.1007/s12020-024-04062-1}
}
Kostenlos starten →